The FDA just approved the world's first mRNA flu shot — and it's not for everyone yet.
Moderna's mFlusiva got the green light for adults 50 and older, built on the same mRNA tech that powered the COVID vaccine, and early trial data says it beats the standard flu shot by 26.6%.
But there's a catch buried in the fine print.
For years, flu shots have barely changed.
Grown in eggs.
Built on old-school viral proteins.
Updated once a year, if the guess about which strain is coming was even right.
Moderna just broke that mold.
Regular flu vaccines contain dead or weakened virus proteins grown painstakingly in chicken eggs — a process that takes months and locks manufacturers into last year's best guess about which strain will circulate.
mFlusiva skips all that.
It hands your cells a set of mRNA instructions — print this flu antigen — and your own body builds the immune response.
Why does that matter?
An FDA advisory panel actually voted 9-0, unanimously, in favor of this vaccine before the agency signed off. That's not a split decision. That's a room full of experts agreeing this thing works.
The approval isn't equal for everyone.
Adults 50 to 64 got a full, traditional approval. Done deal.
Adults 65 and older — the group that actually suffers the worst flu outcomes — got something called accelerated approval.
That's regulator-speak for: we think this works, but Moderna still owes us more proof.
Moderna has to run another study on the 65+ group before this vaccine gets fully locked in for that population.
Stay with that for a second.
The people most vulnerable to flu are the ones this vaccine is least certain about, on paper — even though separate data already showed it outperforming a rival's high-dose shot in exactly that age group.
Moderna's COVID vaccine cash cow has been drying up for years.
The company has been betting its future on flu shots and a combo COVID-flu vaccine to replace that lost revenue and prove mRNA tech isn't a one-hit pandemic wonder.
It hasn't been smooth.
Moderna actually pulled its combo COVID-flu shot application last year after the FDA demanded more evidence on the flu component. That withdrawal happened during a stretch of intense FDA scrutiny under the agency's previous leadership — a period so contentious that former Commissioner Marty Makary and former vaccine chief Vinay Prasad were both forced to resign amid controversy, including fights over this very flu vaccine review.
Now, under acting commissioner Kyle Diamantas, the agency looks like it's trying to rebuild trust with the industry — and this approval is the clearest signal yet.
Here's the reality check.
Moderna missed the contracting window for the 2026 U.S. flu season.
Analysts don't expect mFlusiva to generate meaningful revenue until the second half of 2027.
Jefferies has forecast around $750 million in combined U.S. sales for Moderna's flu shot and future combo vaccine by 2030 — real money, but a slow burn, not an overnight blockbuster.
And it's walking into a crowded room. Sanofi, GSK, CSL Seqirus, and AstraZeneca all already sell flu vaccines to the same 50-plus crowd.
This isn't really a story about one flu season.
It's the first real proof that mRNA technology can move beyond pandemic emergencies and into the vaccines we take every single year.
If mFlusiva earns full approval for seniors down the line, it opens the door for mRNA versions of shingles shots, RSV vaccines, maybe even a combined COVID-flu jab that updates itself as fast as the virus mutates.
The tech that saved the world during COVID just applied for a permanent job.
This was its first performance review.
That's all for now!
